April 26, 2012
Seikagaku Corporation announced on April 24 that it terminated on the same day its licensing agreement with the Finnish research and development venture Biotie Therapies Corp. for the anti-VAP-1 monoclonal antibody developed by Biotie. Although Seikagaku intended to develop the...read more